Salah-Eddin Al-Batran1, Jaffer A Ajani. 1. Quality of Life Working Group of the AIO and Oncology and Hematology Clinic, Krankenhaus Nordwest, Frankfurt, Germany. albatran@aol.com
Abstract
BACKGROUND: Health-related quality of life (HRQoL) is a key issue in patients with metastatic esophagogastric cancer, a disease associated with survival times rarely exceeding 10 months. The objective of the current review was to evaluate the effects of chemotherapy on the HRQoL of patients with metastatic or locally advanced, inoperable esophagogastric cancer. METHODS: A systematic MEDLINE search was performed to address a predefined question list: Does chemotherapy improve or maintain HRQoL? Do available data favor a particular chemotherapy? What relation exists between HRQoL and the efficacy and tolerability of therapy? RESULTS: The majority of studies, including large randomized studies, indicated no significant improvements in mean HRQoL scores versus baseline after chemotherapy. However, scores were maintained and symptomatic relief or improved performance status was observed in many patients. HRQoL was maintained in approximately 50% of patients for up to 6 months but deteriorated in the remaining patients. In randomized phase 3 trials, only cisplatin/fluorouracil plus either docetaxel or epirubicin were found to provide superior HRQoL versus comparators. Between-regimen differences in HRQoL scores appeared to correspond to differences in the efficacy rather than the toxicity of treatment regimens. CONCLUSIONS: Chemotherapy maintained HRQoL in a substantial proportion of patients with advanced esophagogastric cancer. This effect appeared to correspond to the efficacy of the treatment. (c) 2010 American Cancer Society.
BACKGROUND: Health-related quality of life (HRQoL) is a key issue in patients with metastatic esophagogastric cancer, a disease associated with survival times rarely exceeding 10 months. The objective of the current review was to evaluate the effects of chemotherapy on the HRQoL of patients with metastatic or locally advanced, inoperable esophagogastric cancer. METHODS: A systematic MEDLINE search was performed to address a predefined question list: Does chemotherapy improve or maintain HRQoL? Do available data favor a particular chemotherapy? What relation exists between HRQoL and the efficacy and tolerability of therapy? RESULTS: The majority of studies, including large randomized studies, indicated no significant improvements in mean HRQoL scores versus baseline after chemotherapy. However, scores were maintained and symptomatic relief or improved performance status was observed in many patients. HRQoL was maintained in approximately 50% of patients for up to 6 months but deteriorated in the remaining patients. In randomized phase 3 trials, only cisplatin/fluorouracil plus either docetaxel or epirubicin were found to provide superior HRQoL versus comparators. Between-regimen differences in HRQoL scores appeared to correspond to differences in the efficacy rather than the toxicity of treatment regimens. CONCLUSIONS: Chemotherapy maintained HRQoL in a substantial proportion of patients with advanced esophagogastric cancer. This effect appeared to correspond to the efficacy of the treatment. (c) 2010 American Cancer Society.
Authors: Taroh Satoh; Yung-Jue Bang; Evgeny A Gotovkin; Yasuo Hamamoto; Yoon-Koo Kang; Vladimir M Moiseyenko; Atsushi Ohtsu; Eric Van Cutsem; Nedal Al-Sakaff; Alexa Urspruch; Julie Hill; Harald A Weber; Hyun-Cheol Chung Journal: Oncologist Date: 2014-06-20
Authors: Vincent T Janmaat; Ewout W Steyerberg; Ate van der Gaast; Ron Hj Mathijssen; Marco J Bruno; Maikel P Peppelenbosch; Ernst J Kuipers; Manon Cw Spaander Journal: Cochrane Database Syst Rev Date: 2017-11-28
Authors: Ilufredo Y Tantoy; Bruce A Cooper; Anand Dhruva; Janine Cataldo; Steven M Paul; Yvette P Conley; Marilyn Hammer; Kord M Kober; Jon D Levine; Christine Miaskowski Journal: Qual Life Res Date: 2018-04-21 Impact factor: 4.147
Authors: Paolo Piacentini; Emilia Durante; Annarita Trolese; Anna Mercanti; Andrea Bonetti Journal: Gastric Cancer Date: 2011-08-17 Impact factor: 7.370
Authors: Mohammad-Kazem Atef-Vahid; Mehdi Nasr-Esfahani; Mohsen Saberi Esfeedvajani; Homayoon Naji-Isfahani; Mohammad Reza Shojaei; Yasavoli M Masoumeh; S Ashrafodin Goushegir Journal: J Res Med Sci Date: 2011-07 Impact factor: 1.852
Authors: N Haj Mohammad; E ter Veer; L Ngai; R Mali; M G H van Oijen; H W M van Laarhoven Journal: Cancer Metastasis Rev Date: 2015-09 Impact factor: 9.264